Sanochemia: New contrast agent aims to detect the smallest lymphatic metastases in prostate cancer
NEUFELD, Austria, April 17, 2024 /PRNewswire/ -- Sanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the …